Precigen Inc (PGEN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.63B
Last updated: Nov 17, 2026 at 11:06 AM ET
Precigen Inc (PGEN) Financials: Revenue, Profit and Cash Flow
Precigen reported revenue of $9.68M for the fiscal year ended Dec 31, 2025, up 146.7% from the year before. That year, net income was -$250.64M with a net margin of -2588.2%, operating cash flow was -$87.83M and free cash flow was -$89.83M. The quarter ended Sep 30, 2026 had revenue of $74.15M and net income of $35.77M.
Revenue and Margins
Over the 9 years to Dec 2025, revenue fell from $190.93M, a compound annual decline of 28.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $9.68M | +146.7% | 50.2% | -1141.1% | -2588.2% |
| Dec 2024 | $3.92M | -36.9% | -8.7% | -3440.2% | -3216.2% |
| Dec 2023 | $6.22M | -76.9% | 1.7% | -1602.5% | -1540.6% |
| Dec 2022 | $26.91M | +88.6% | 76.4% | -281.4% | 130.4% |
| Dec 2021 | $14.27M | -55.4% | 59.7% | -644.5% | -646.0% |
| Dec 2020 | $31.99M | N/A | 83.2% | 11.4% | -198.5% |
| Dec 2019 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2018 | $160.57M | -30.5% | 60.6% | -314.9% | -317.2% |
| Dec 2017 | $230.98M | +21.0% | 72.8% | -59.7% | -50.7% |
| Dec 2016 | $190.93M | N/A | 67.7% | -65.6% | -99.7% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.68M | $3.92M | $6.22M | $26.91M | $14.27M | $31.99M | $0 | $160.57M | $230.98M | $190.93M |
| Cost of revenue | $4.82M | $4.27M | $6.12M | $6.34M | $5.75M | $5.37M | $61.40M | $63.29M | $62.79M | $61.64M |
| Gross profit | $4.86M | -$342.00K | $106.00K | $20.57M | $8.52M | $26.62M | -$61.40M | $97.29M | $168.19M | $129.29M |
| Research and development | $41.33M | $53.07M | $48.61M | $47.17M | $47.93M | $0 | $66.67M | $404.59M | $143.21M | $112.14M |
| Operating income | -$110.51M | -$135.03M | -$99.76M | -$75.73M | -$91.95M | $3.66M | -$166.79M | -$505.61M | -$137.89M | -$125.17M |
| Net income | -$250.64M | -$126.23M | -$95.90M | $35.09M | -$92.17M | -$63.52M | -$646.24M | -$509.34M | -$117.02M | -$190.27M |
| EBITDA | N/A | -$125.80M | -$94.21M | -$61.55M | -$65.65M | $31.06M | -$129.99M | -$349.06M | -$97.94M | -$38.93M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $74.15M | $54.98M | $23.25M | $3.71M | $2.92M | $856.00K | $1.34M | $473.00K | $953.00K | $1.43M | $1.06M | $1.23M |
| Gross profit | $67.64M | $52.17M | $20.69M | $2.11M | $1.89M | -$236.00K | $241.00K | -$696.00K | -$56.00K | $420.00K | -$10.00K | -$130.00K |
| Operating income | $38.65M | $22.64M | -$5.99M | -$21.67M | -$34.48M | -$31.76M | -$22.60M | -$28.52M | -$21.26M | -$60.84M | -$24.41M | -$34.22M |
| Net income | $35.77M | $20.07M | -$7.93M | -$23.50M | -$146.34M | -$26.64M | -$54.15M | -$19.73M | -$23.98M | -$58.79M | -$23.74M | -$33.06M |
Balance Sheet
As of Dec 2025, total debt of $94.31M exceeded cash and equivalents by $64.08M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $155.50M | $145.27M | $151.04M | $215.98M | $359.86M | $314.59M | $455.76M | $716.18M | $846.85M | $949.07M |
| Current assets | $115.23M | $102.41M | $68.75M | $118.16M | $156.63M | $148.95M | $234.64M | $285.48M | $154.05M | $315.18M |
| Cash and equivalents | $30.23M | $29.52M | $7.58M | $4.86M | $36.42M | $51.79M | $65.79M | $96.88M | $68.11M | $62.61M |
| Total liabilities | $134.59M | $78.53M | $32.55M | $89.72M | $252.51M | $247.41M | $384.05M | $337.45M | $300.31M | $379.82M |
| Short-term debt | $1.14M | $956.00K | $1.20M | $43.22M | $52.00K | $360.00K | $33.59M | $945.00K | $735.00K | $1.21M |
| Long-term debt | $93.17M | $0 | N/A | N/A | $179.88M | $171.52M | $186.32M | $211.22M | $7.54M | $7.56M |
| Shareholder equity | $20.91M | $38.51M | $118.50M | $126.26M | $107.35M | $67.17M | $71.71M | $362.86M | $533.63M | $560.24M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $212.10M | $170.30M | $138.63M | $156.62M | $171.26M | $101.90M | $128.79M | $145.27M | $83.47M | $73.16M | $134.85M | $151.04M |
| Total liabilities | $128.31M | $126.72M | $118.39M | $135.71M | $129.40M | $107.79M | $113.33M | $106.75M | $28.10M | $29.99M | $37.83M | $32.55M |
| Cash and equivalents | $14.96M | $16.33M | $7.48M | $30.23M | $14.32M | $13.76M | $6.06M | $29.52M | $24.73M | $9.35M | $17.48M | $7.58M |
| Shareholder equity | $83.79M | $43.58M | $20.23M | $20.91M | $41.87M | -$36.78M | -$14.06M | $38.51M | $55.38M | $43.17M | $97.02M | $118.50M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$87.83M | -$68.17M | -$66.93M | -$65.05M | -$55.77M | -$77.02M | -$135.93M | -$124.24M | -$103.72M | -$48.99M |
| Capital expenditures | $2.00M | $8.58M | $1.54M | $4.92M | $7.25M | $7.53M | $37.88M | $41.59M | $46.67M | $31.63M |
| Free cash flow | -$89.83M | -$76.76M | -$68.47M | -$69.97M | -$63.02M | -$84.55M | -$173.81M | -$165.83M | -$150.39M | -$80.62M |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $913.00K | $41.98M |
| Share repurchases | N/A | N/A | N/A | N/A | N/A | $0 | N/A | N/A | $10.00K | $0 |
| Investing cash flow | -$1.53M | -$20.71M | -$3.09M | $226.42M | -$74.54M | $27.78M | $86.85M | -$151.21M | $104.33M | -$28.39M |
| Financing cash flow | $90.05M | $110.58M | $29.59M | -$155.29M | $121.19M | $32.70M | $8.14M | $309.80M | $4.28M | $12.06M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $11.88M | -$17.81M | -$43.83M | -$23.46M | -$29.07M | -$18.98M | -$16.32M | -$8.24M | -$22.73M | -$23.11M | -$14.09M | -$15.77M |
| Capital expenditures | $435.00K | $392.00K | $258.00K | $18.00K | $389.00K | $966.00K | $622.00K | $1.03M | $882.00K | $2.32M | $4.35M | $1.04M |
| Free cash flow | $11.45M | -$18.20M | -$44.09M | -$23.48M | -$29.46M | -$19.94M | -$16.95M | -$9.27M | -$23.61M | -$25.43M | -$18.44M | -$16.81M |
Frequently Asked Questions About PGEN
What is Precigen's annual revenue?
Precigen reported revenue of $9.68M for the fiscal year ended Dec 31, 2025.
How fast is Precigen's revenue growing?
Revenue was up 146.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -28.9%.
Is Precigen profitable?
No. Precigen reported net income of -$250.64M for the fiscal year ended Dec 31, 2025, with a net margin of -2588.2%.
How much free cash flow does PGEN generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$87.83M minus capital expenditures of $2.00M produced free cash flow of -$89.83M.
How much debt does Precigen have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $93.17M, short-term debt of $1.14M and cash and equivalents of $30.23M.
PGEN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors